Can artificial intelligence accelerate preclinical drug discovery and precision medicine?

Ali Farnouda Institute of Computational Biology, Helmholtz Center Munich, Munich, GermanyView further author information

Alexander J. Ohnmachta Institute of Computational Biology, Helmholtz Center Munich, Munich, Germany;b Department of Biology, Ludwig-Maximilians University Munich, Munich, Germany

https://orcid.org/0000-0002-1481-9426 View further author information

Martin Meinela Institute of Computational Biology, Helmholtz Center Munich, Munich, Germany;c Department of Dermatology and Allergy, Technical University Munich, Munich, Germany

https://orcid.org/0000-0002-4042-6247 View further author information

Michael P. Mendena Institute of Computational Biology, Helmholtz Center Munich, Munich, Germany;b Department of Biology, Ludwig-Maximilians University Munich, Munich, Germany;d German Center for Diabetes Research (DZD e.V.), Munich, GermanyCorrespondence[email protected]

https://orcid.org/0000-0003-0267-5792 View further author information

Click to increase image sizeClick to decrease image size

Declaration of Interest

MP Menden is a former employee of AstraZeneca who collaborates with GlaxoSmithKline, AstraZeneca and Roche. He also declares research funding from GlaxoSmithKline and Roche. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Reviewer disclosures

Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.

Additional information

Funding

The authors are supported by a H2020 European Research Council grant under No. 950293.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Can artificial intelligence accelerate preclinical drug discovery and precision medicine?

Information for

Open access

Opportunities

Help and information

Can artificial intelligence accelerate preclinical drug discovery and precision medicine?

Declaration of Interest

Reviewer disclosures

Additional information

Funding

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature